Perigon Wealth Management LLC Purchases 94 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Perigon Wealth Management LLC lifted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 4,943 shares of the pharmaceutical company’s stock after acquiring an additional 94 shares during the quarter. Perigon Wealth Management LLC’s holdings in Vertex Pharmaceuticals were worth $2,061,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Czech National Bank boosted its stake in Vertex Pharmaceuticals by 6.2% in the 4th quarter. Czech National Bank now owns 55,838 shares of the pharmaceutical company’s stock worth $22,486,000 after purchasing an additional 3,260 shares during the period. Whalen Wealth Management Inc. bought a new position in Vertex Pharmaceuticals in the 3rd quarter worth about $662,000. Mizuho Securities USA LLC boosted its stake in Vertex Pharmaceuticals by 289.0% in the 3rd quarter. Mizuho Securities USA LLC now owns 77,393 shares of the pharmaceutical company’s stock worth $35,994,000 after purchasing an additional 57,497 shares during the period. Nordea Investment Management AB boosted its stake in Vertex Pharmaceuticals by 19.4% in the 4th quarter. Nordea Investment Management AB now owns 342,429 shares of the pharmaceutical company’s stock worth $137,783,000 after purchasing an additional 55,739 shares during the period. Finally, Keynote Financial Services LLC bought a new position in Vertex Pharmaceuticals in the 3rd quarter worth about $498,000. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

VRTX opened at $441.52 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The stock has a market capitalization of $113.70 billion, a PE ratio of -221.87, a price-to-earnings-growth ratio of 2.20 and a beta of 0.40. The stock’s 50 day moving average price is $434.75 and its 200-day moving average price is $463.64.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The firm had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.69 billion. During the same period in the previous year, the firm earned $3.67 earnings per share. The business’s revenue was up 11.6% compared to the same quarter last year. On average, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current year.

Analyst Ratings Changes

Several brokerages have commented on VRTX. Scotiabank raised their target price on Vertex Pharmaceuticals from $426.00 to $430.00 and gave the stock a “sector perform” rating in a research note on Monday, December 23rd. Barclays cut their target price on Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating for the company in a research note on Friday, December 20th. HC Wainwright lowered their price target on Vertex Pharmaceuticals from $600.00 to $535.00 and set a “buy” rating on the stock in a report on Friday, December 20th. Jefferies Financial Group raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price target for the company from $500.00 to $550.00 in a report on Monday, December 9th. Finally, Wells Fargo & Company lowered their price target on Vertex Pharmaceuticals from $555.00 to $460.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $494.76.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.